<DOC>
	<DOCNO>NCT00705653</DOCNO>
	<brief_summary>This phase I study aim assess safety tolerability new drug - PG-11047 - establish happens drug inside body . An escalate dose PG-11047 investigate study maximum tolerate dose drug establish .</brief_summary>
	<brief_title>Study CGC-11047 ( PG-11047 ) Subjects With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>This open-label phase I , dose-escalation safety study subject refractory solid tumor . The primary objective study assess safety , tolerability , pharmacokinetics PG-11047 . PG-11047 administer 60-minute intravenous infusion day 1 , 8 15 28 day cycle . The planned minimum treatment schedule 2 cycle ( 8 week ) PG-11047 treatment . Subjects tolerate treatment may eligible receive additional cycle per investigator 's medical judgment . Evaluation anti-tumor response perform every 2 cycle .</detailed_description>
	<mesh_term>N ( 1 ) , N ( 11 ) -diethylnorspermine</mesh_term>
	<criteria>nonhematological malignancy standard therapeutic measure exist longer effective . ECOG 02 . Life expectancy &gt; 3 month . chemotherapy radiotherapy within 4 week prior enter study . previous highdose chemotherapy autologous allogeneic hematopoietic stem cell transplantation . primary brain tumor active brain metastasis history significant symptomatic cardiac arrhythmia , prior myocardial infarction evidence current significant ventricular conduction abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>CGC-11047</keyword>
	<keyword>PG-11047</keyword>
</DOC>